Katherine R. Courtright

Katherine R. Courtright

Auto-generated profile, based on publicly available information

Katherine R. Courtright

Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2021 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
CACatherine L. Auriemma
Catherine L. Auriemma
STStephanie P. Taylor
Stephanie P. Taylor
MHMichael O. Harhay
Michael O. Harhay
KCKatherine R. Courtright
Katherine R. Courtright
SHScott D. Halpern
Scott D. Halpern
Hospital-free days (HFDs), alternatively known as “days alive and outside the hospital,” is increasingly used as a primary or secondary outcome in randomized trials among critically and seriously ill patients. This novel outcome measure addresses an existing gap in the availability of patient-centered, reliably obtained outcome measures among patients with acute respiratory failure, advanced lung diseases, lung transplantation, and other serious and critical illnesses. Traditional outcomes such as mortality, organ-failure-free days, and longitudinal patient-reported measures have distinct drawbacks that limit their suitability as endpoints in trials of patients with serious illness, particularly those trials with pragmatic designs. By contrast, HFDs provides a summary measure of important health events and is easily calculated from administrative or electronic health record data, thereby balancing the goals of patient-centeredness and pragmatic measurement. However, before HFDs can be widely adopted as an endpoint in trials of patients with respiratory and critical illnesses, several questions must be addressed regarding the optimal definition, measurement, and analysis of HFDs. In this perspective, we outline important considerations relevant to the use of HFDs as a trial endpoint and suggest directions for further development of the measure.

1 May 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
GAGeorge L. Anesi
George L. Anesi
JJJuliane Jablonski
Juliane Jablonski
MHMichael O. Harhay
Michael O. Harhay
JAJoshua H. Atkins
Joshua H. Atkins
JBJasmeet Bajaj
Jasmeet Bajaj
JGJacob T. Gutsche
Jacob T. Gutsche
This study examined whether mortality, receipt of mechanical ventilation, and patient acuity changed over time among adult patients with COVID-19–related critical illness admitted to intensive care... Visual COVID-19–Related Critical Illness In a large health system in the United States, investigators examined whether mortality, receipt of mechanical ventilation, and patient acuity chan... Background: The coronavirus disease 2019 (COVID-19) pandemic continues to surge in the United States and globally. Objective: To describe the epidemiology of COVID-19–related critical illness, incl...

16 July 2019 in Journal of General Internal Medicine
Verified
Journal Article
Open access
PDF file
KCKatherine R. Courtright
Katherine R. Courtright
CCCorey Chivers
Corey Chivers
MBMichael Becker
Michael Becker
SRSusan H. Regli
Susan H. Regli
LPLinnea C. Pepper
Linnea C. Pepper
NONina R. O’connor
Nina R. O’connor
Background Development of electronic health record (EHR) prediction models to improve palliative care delivery is on the rise, yet the clinical impact of such models has not been evaluated. Objective To assess the clinical impact of triggering palliative care using an EHR prediction model. Design Pilot prospective before-after study on the general medical wards at an urban academic medical center. Participants Adults with a predicted probability of 6-month mortality of ≥ 0.3. Intervention Triggered (with opt-out) palliative care consult on hospital day 2. Main Measures Frequencies of consults, advance care planning (ACP) documentation, home palliative care and hospice referrals, code status changes, and pre-consult length of stay (LOS). Key Results The control and intervention periods included 8 weeks each and 138 admissions and 134 admissions, respectively. Characteristics between the groups were similar, with a mean (standard deviation) risk of 6-month mortality of 0.5 (0.2). Seventy-seven (57%) triggered consults were accepted by the primary team and 8 consults were requested per usual care during the intervention period. Compared to historical controls, consultation increased by 74% (22 [16%] vs 85 [63%], P < .001), median (interquartile range) pre-consult LOS decreased by 1.4 days (2.6 [1.1, 6.2] vs 1.2 [0.8, 2.7], P = .02), ACP documentation increased by 38% (23 [17%] vs 37 [28%], P = .03), and home palliative care referrals increased by 61% (9 [7%] vs 23 [17%], P = .01). There were no differences between the control and intervention groups in hospice referrals (14 [10] vs 22 [16], P = .13), code status changes (42 [30] vs 39 [29]; P = .81), or consult requests for lower risk (< 0.3) patients (48/1004 [5] vs 33/798 [4]; P = .48). Conclusions Targeting hospital-based palliative care using an EHR mortality prediction model is a clinically promising approach to improve the quality of care among seriously ill medical patients. More evidence is needed to determine the generalizability of this approach and its impact on patient- and caregiver-reported outcomes.

1 February 2024 in Annals of the American Thoracic Society
Verified
Journal Article
Open access
JKJacqueline M. Kruser
Jacqueline M. Kruser
DADeepshikha C. Ashana
Deepshikha C. Ashana
KCKatherine R. Courtright
Katherine R. Courtright
EKErin K. Kross
Erin K. Kross
TNThanh H. Neville
Thanh H. Neville
CCChristopher E. Cox
Christopher E. Cox
In critical care, the specific, structured approach to patient care known as a “time-limited trial” has been promoted in the literature to help patients, surrogate decision makers, and clinicians navigate consequential decisions about life-sustaining therapy in the face of uncertainty. Despite promotion of the time-limited trial approach, a lack of consensus about its definition and essential elements prevents optimal clinical use and rigorous evaluation of its impact. The objectives of this American Thoracic Society Workshop Committee were to establish a consensus definition of a time-limited trial in critical care, identify the essential elements for conducting a time-limited trial, and prioritize directions for future work. We achieved these objectives through a structured search of the literature, a modified Delphi process with 100 interdisciplinary and interprofessional stakeholders, and iterative committee discussions. We conclude that a time-limited trial for patients with critical illness is a collaborative plan among clinicians and a patient and/or their surrogate decision makers to use life-sustaining therapy for a defined duration, after which the patient’s response to therapy informs the decision to continue care directed toward recovery, transition to care focused exclusively on comfort, or extend the trial’s duration. The plan’s 16 essential elements follow four sequential phases: consider, plan, support, and reassess. We acknowledge considerable gaps in evidence about the impact of time-limited trials and highlight a concern that if inadequately implemented, time-limited trials may perpetuate unintended harm. Future work is needed to better implement this defined, specific approach to care in practice through a person-centered equity lens and to evaluate its impact on patients, surrogates, and clinicians.

5 February 2020 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
KCKatherine R. Courtright
Katherine R. Courtright
LJLizeyka Jordan
Lizeyka Jordan
CMChristopher M. Murtaugh
Christopher M. Murtaugh
YBYolanda Barrón
Yolanda Barrón
PDPartha Deb
Partha Deb
MMMark E. Mikkelsen
Mark E. Mikkelsen
Although sepsis is common, reductions in hospital mortality have led to an increasing number of survivors,1,2 with more than 1 million patients being discharged after treatment of sepsis from United States hospitals each year.3 However, sepsis survivorship often comes at a cost, namely reduced health-related quality of life, cognitive and functional impairments,4 increased risks of hospital readmission,5-7 and long-term mortality risk.8-11 Amid a heightened awareness of these long-term consequences,12,13 improving the quality of post-sepsis care has become a global priority.13

15 November 2021 in Critical Care
Verified
Journal Article
Open access
PDF file
DKDustin C. Krutsinger
Dustin C. Krutsinger
KYKuldeep N. Yadav
Kuldeep N. Yadav
MHMichael O. Harhay
Michael O. Harhay
KBKarsten Bartels
Karsten Bartels
KCKatherine R. Courtright
Katherine R. Courtright
Background: Enrollment problems are common among randomized controlled trials conducted in the ICU. However, little is known about actual trial enrollment rates and influential factors. We set out to determine the overall enrollment rate in recent randomized controlled trials (RCTs) of patients with acute respiratory distress syndrome (ARDS), acute lung injury (ALI), or sepsis, and which factors influenced enrollment rate.Methods: We conducted a systematic review by searching Pubmed using predefined terms for ARDS/ALI and sepsis to identify individually RCTs published among the seven highest impact general medicine and seven highest impact critical care journals between 2009 and 2019. Cluster randomized trials were excluded. Data were extracted by two independent reviewers using an electronic database management system. We conducted a random-effects meta-analysis of the eligible trials for the primary outcome of enrollment rate by time and site.Results: Out of 457 articles identified, 94 trials met inclusion criteria. Trials most commonly evaluated pharmaceutical interventions (53%), were non-industry funded (78%), and required prospective informed consent (81%). The overall mean enrollment rate was 0.83 (95% confidence interval: 0.57–1.21) participants per month per site. Enrollment in ARDS/ALI and sepsis trials were 0.48 (95% CI 0.32–0.70) and 0.98 (95% CI 0.62–1.56) respectively. The enrollment rate was significantly higher for single-center trials (4.86; 95% CI 2.49–9.51) than multicenter trials (0.52; 95% CI 0.41–0.66). Of the 36 trials that enrolled < 95% of the target sample size, 8 (22%) reported slow enrollment as the reason.Conclusions: In this systematic review and meta-analysis, recent ARDS/ALI and sepsis clinical trials had an overall enrollment rate of less than 1 participant per site per month. Novel approaches to improve critical care trial enrollment efficiency are needed to facilitate the translation of best evidence into practice.